SNMMI annual meeting featured a clinical diagnosis and therapy session and a presentation by Dr. Kambiz Rahbar discussing the utility of the PROSTest to predict response to 177 Lu-PSMA therapy in ...

SNMMI annual meeting featured a clinical diagnosis and therapy session and a presentation by Dr. Kambiz Rahbar discussing the clinical value of the PROSTest to detect biochemical recurrence in ...

Zachary Klaassen speaks with Adrien Holzgreve about the FLEX-MRT trial, which aims to personalize lutetium-177 PSMA radioligand therapy delivery. Currently, Pluvicto™ follows fixed dosing from the ...

PSMA PET prognosis, PROMISE registry, PSMA PET survival prediction, prostate cancer prognostic biomarker, PSMA PET risk stratification, Emerging Prognostic Value of Molecular Imaging in Prostate ...

Evan Yu is joined by Atish Choudhury to discuss a first-in-human trial combining EZH2 and PARP inhibition in metastatic castration-resistant prostate cancer. Dr. Choudhury explains that EZH2 is an ...

SNMMI 2025 novel PSMA-targeting drug 177Lu-P17-088, metastatic castration-resistant prostate cancer (mCRPC), VISION and PSMAfore trials, PCWG3 guidelines.

(TROG 08.03/ANZUP RAVES) Phase 3 Trial on Adjuvant Radiotherapy Versus Early Salvage Radiotherapy Following Radical Prostatectomy Journal Club - Christopher Wallis & Zachary Klaassen Adjuvant or Early ...

Clear explanation of what a "Foley" or indwelling catheter is, the 2 types of insertions, their use cases, and the risk of CAUTI if catheterization isn't properly managed.

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

ASCO 2025, bladder cancer, Muscle Invasive Bladder Cancer (MIBC), Sasanlimab, SASAN-SPARING trial, Sasanlimab as Bladder-Sparing Maintenance Treatment After Neoadjuvant Chemotherapy, Whole-exome ...

(UroToday.com) The 2025 SNMMI annual meeting featured a prostate cancer and dosimetry session and a presentation by Dr. Sabina Dizdarevic discussing eight-year follow-up of patient outcomes and bone ...

ASCO 2025 First PARP Inhibitor Combo to Show Benefit in mCSPC Johnson & Johnson's AKEEGA® (niraparib + abiraterone acetate) is the first PARP-based combination to demonstrate statistically significant ...